Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review
- PMID: 33209439
- PMCID: PMC7656369
- DOI: 10.21037/jtd-20-1810
Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review
Abstract
In December 2019, the coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered. Since its emergence, COVID-19 has been outbreaking rapidly worldwide, where the virus has so far caused the death of hundreds of thousands and infected more than a million, what has been called a pandemic by the World Health Organization (WHO). According to the WHO-Coronavirus disease 2019 Situation Report-142, by June 10, 2020, there are 7,145,539 confirmed cases and 408,025 deaths. There is an urgent need to develop a suitable specific medicine against this novel coronavirus; therefore, scientists and researchers around the world are making great efforts endeavoring to discover an efficient specific medication for COVID-19 treatment. Given the similarity of the novel coronavirus with previous epidemic viruses, namely, the acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), previously tested drugs could potentially work against the novel coronavirus. In this narrative review, we aim to summarize and discuss the effectiveness of current Western medicine and traditional Chinese medicine options for COVID-19 treatment based on the overview of the scientific literature. Some Western medicines including remdesivir, chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, and arbidol, as well as some traditional Chinese medicine (TCM) such as Qingfei Paidu decoction, Yupingfeng, Lianhua Qingwen, and TCM injections have revealed a relative activity against SARS-CoV-2 in vitro, in observational studies, and in clinical trials. However, further extensive studies and clinical trials including double-blind and randomized clinical trials, with a higher number of patients, are necessary to confirm the activity of these medicines. There are several ongoing trials conducted on the drugs of COVID-19, and the results are urgently needed to make a suitable treatment recommendation.
Keywords: Coronavirus disease 2019 (COVID-19); coronavirus; traditional Chinese medicine (TCM); treatment.
2020 Journal of Thoracic Disease. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-1810). The authors have no conflicts of interest to declare.
Similar articles
-
Potential herb‒drug interactions between anti-COVID-19 drugs and traditional Chinese medicine.Acta Pharm Sin B. 2023 Jun 5;13(9):3598-637. doi: 10.1016/j.apsb.2023.06.001. Online ahead of print. Acta Pharm Sin B. 2023. PMID: 37360014 Free PMC article. Review.
-
The journey of remdesivir: from Ebola to COVID-19.Drugs Context. 2020 May 22;9:2020-4-14. doi: 10.7573/dic.2020-4-14. eCollection 2020. Drugs Context. 2020. PMID: 32547625 Free PMC article. Review.
-
Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19.Am J Chin Med. 2021;49(4):785-803. doi: 10.1142/S0192415X21500373. Epub 2021 Apr 9. Am J Chin Med. 2021. PMID: 33853498 Review.
-
New insights for infection mechanism and potential targets of COVID-19: Three Chinese patent medicines and three Chinese medicine formulas as promising therapeutic approaches.Chin Herb Med. 2023 Apr;15(2):157-168. doi: 10.1016/j.chmed.2022.06.014. Epub 2023 Mar 8. Chin Herb Med. 2023. PMID: 37220535 Free PMC article. Review.
-
Current status of traditional Chinese medicine for the treatment of COVID-19 in China.Chin Med. 2021 Jul 27;16(1):63. doi: 10.1186/s13020-021-00461-y. Chin Med. 2021. PMID: 34315521 Free PMC article. Review.
Cited by
-
Polygoni multiflori radix extracts inhibit SARS-CoV-2 pseudovirus entry in HEK293T cells and zebrafish larvae.Phytomedicine. 2022 Jul 20;102:154154. doi: 10.1016/j.phymed.2022.154154. Epub 2022 May 9. Phytomedicine. 2022. PMID: 35576740 Free PMC article.
-
Neuromasts and Olfactory Organs of Zebrafish Larvae Represent Possible Sites of SARS-CoV-2 Pseudovirus Host Cell Entry.J Virol. 2022 Dec 21;96(24):e0141822. doi: 10.1128/jvi.01418-22. Epub 2022 Nov 30. J Virol. 2022. PMID: 36448804 Free PMC article.
-
Traditional Chinese Medicine, Qingfei Paidu Decoction and Xuanfei Baidu Decoction, Inhibited Cytokine Production via NF-κB Signaling Pathway in Macrophages: Implications for Coronavirus Disease 2019 (COVID-19) Therapy.Front Pharmacol. 2021 Oct 26;12:722126. doi: 10.3389/fphar.2021.722126. eCollection 2021. Front Pharmacol. 2021. PMID: 34764867 Free PMC article.
-
Practices, Knowledge, and Attitudes of Chinese University Students Toward Traditional Chinese Herbal Medicine for the Control of COVID-19.Infect Drug Resist. 2022 Nov 30;15:6951-6962. doi: 10.2147/IDR.S387292. eCollection 2022. Infect Drug Resist. 2022. PMID: 36474905 Free PMC article.
-
Traditional Chinese medicine in COVID-19.Acta Pharm Sin B. 2021 Nov;11(11):3337-3363. doi: 10.1016/j.apsb.2021.09.008. Epub 2021 Sep 20. Acta Pharm Sin B. 2021. PMID: 34567957 Free PMC article. Review.
References
-
- US Centers for Disease Control and Prevention (CDC). Coronavirus disease 2019 (COVID- 19). Available online: https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/high-risk- com...
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous